Clinical Trial

Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL

Study acronym: ASCT DLBCL
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the efficacy and safety of the Glofitamab bridging ASCT regimen in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and to provide better clinical benefits to these patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-07.
Trial Details
NCT Number NCT06682130
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions Diffuse Large B-cell Lymphoma(DLBCL)
Enrollment 40 participants
Start Date 2024-11-10
Primary Completion 2027-11-10 (estimated)
Study Completion 2029-11-10 (estimated)
Updated on ClinicalTrials.gov 2025-07-14